Incuron Announces Notice of Allowance from FDA to Commence Clinical Trials of CBL0137.
Incuron Announces Results in Study of Pediatric Neuroblastoma, that have been published in the journal Science Translational Medicine. The reported studies were led by scientists from the Children’s Cancer Institute–Australia (CCIA),Roswell Park Cancer Institute (RPCI) and Incuron.
Cell Reports Publication Elucidates Role of FACT as Accelerator of Tumor Transformation and Potential Marker and Target of Aggressive Cancers
Incuron Announces Updates on Clinical Progress with CBL0137
Incuron, LLC Announces Start of US Trial With CBL0137
Science Translational Medicine Publishes Breakthrough Finding From Cleveland BioLabs and Incuron on Identification of Target and Mechanism of Action of Novel Anticancer Agents Curaxins
Incuron Announce CBL0102 Orphan Drug Status for Hepatocellular Carcinoma
Incuron Announce Notice of Allowance from FDA to Commence Clinical Testing with CBL0137.
Incuron, LLC announces start of a phase Ib safety and tolerability trial for curaxin CBL0102 in patients with liver tumors of different etiology in Russia